Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

300.00
-28.9299-8.80%
Volume:78.08K
Turnover:23.79M
Market Cap:8.22B
PE:-23.21
High:315.00
Open:315.00
Low:293.01
Close:328.93
52wk High:335.75
52wk Low:26.70
Shares:27.41M
Float Shares:22.92M
Volume Ratio:7.92
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:23.94
PE(LYR):-29.38

Loading ...

Stock Track | Praxis Precision Medicines Plummets 5.92% Intraday After Q4 Earnings Miss and Widening Losses

Stock Track
·
Just now

Praxis Precision Medicines Publishes Corporate Presentation on CNS Pipeline and Commercial Launch Plans

Reuters
·
1 hour ago

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q4 Loss $3.50 a Share, vs. FactSet Est of $2.88 Loss

MT Newswires Live
·
1 hour ago

Praxis Precision posts bigger Q4 loss as R&D costs grow

Reuters
·
1 hour ago

Praxis Precision Medicine Q4 EPS $(3.50) Misses $(3.08) Estimate

Benzinga
·
2 hours ago

Praxis reports FY 2025 R&D expenses up 1.75x to USD 267.1 million

Reuters
·
2 hours ago

BRIEF-Praxis Precision Q4 EPS USD -3.5

Reuters
·
2 hours ago

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Dow Jones
·
2 hours ago

Earning Preview: Praxis Precision Medicines, Inc. Q4 revenue is expected to decrease by 88.06%, and institutional views are bullish

Earnings Agent
·
Feb 12

Praxis Precision Medicines Updates Non-Employee Director Compensation Policy

Reuters
·
Feb 11

Praxis Precision Med Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 10

Praxis Precision Medicines Inc. published an update to their financial calendar

Reuters
·
Feb 10

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 10

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Feb 09

Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan

Reuters
·
Feb 05

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 05

Praxis Precision Med Is Maintained at Buy by Needham

Dow Jones
·
Feb 04

Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis

TIPRANKS
·
Feb 04

Praxis Precision Med Initiated at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 02

Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target

MT Newswires Live
·
Feb 02